EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

In vivo LNP-CRISPR Approaches for the Treatment of Hemophilia

Jeong Hyeon Lee, Jeong Pil Han iD

Molecular Diagnosis & Therapy · 2024

DOI: 10.1007/s40291-024-00705-1 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Molecular Diagnosis & Therapy, 2024. Verfasst von Jeong Hyeon Lee und 1 weiteren Autor:innen. Beteiligte Einrichtung: Graduate School of International Agricultural Technology, Institute of Green BioScience and Technology, Seoul National University, 1447 Pyeongchang-r…. Hauptthemen laut MEDLINE: Hemophilia A, Gene Editing, Genetic Therapy, CRISPR-Cas Systems. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 100 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Seoul National University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hemophilia is a genetic disorder that is caused by mutations in coagulation factor VIII (hemophilia A) or IX (hemophilia B) genes resulting in blood clotting disorders. Despite advances in therapies, such as recombinant proteins and products with extended half-lives, the treatment of hemophilia still faces two major limitations: the short duration of therapeutic effect and production of neutralizing antibodies against clotting factors (inhibitor). To overcome these limitations, new hemophilia treatment strategies have been established such as gene therapy, bispecific antibody, and rebalancing therapy. Although these strategies have shown promising results, it is difficult to achieve a permanent therapeutic effect. Advances in the clustered regularly interspaced short palindromic repeat (CRISPR) technology have allowed sustainable treatment by correcting mutated genes. Since genome editing generates irreversible changes in host genome, safety must be ensured by delivering target organs. Therefore, the delivery tool of the CRISPR system is crucial for safe, accurate, and efficient genome editing. Recently, non-viral vector lipid nanoparticles (LNPs) have emerged as safer tools for delivering CRISPR systems than other viral vectors. Several previous hemophilia pre-clinical studies using LNP-CRISPR showed that sufficient and sustainable therapeutic effects, which means that LNP-CRISPR-mediated genome-editing therapy can be a valid option for the treatment of hemophilia. In this paper, we summarize the latest advancements in the successful treatment of hemophilia and the potential of CRISPR-mediated genome-editing therapy using LNPs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hemophilia AGene EditingGenetic TherapyCRISPR-Cas SystemsNanoparticlesHumansAnimalsHemophilia BFactor VIIILipidsGenetic VectorsClustered Regularly Interspaced Short Palindromic Repeats

Substanzen

Factor VIIILipids

Autor:innen und Institutionen

  • Graduate School of International Agricultural Technology, Institute of Green BioScience and Technology, Seoul National University, 1447 Pyeongchang-ro, Daewha, Pyeongchang, 25354, Gangwon, Korea.
  • Graduate School of International Agricultural Technology, Institute of Green BioScience and Technology, Seoul National University, 1447 Pyeongchang-ro, Daewha, Pyeongchang, 25354, Gangwon, Korea. pil1426@snu.ac.kr.

ORCID-Profile: Jeong Pil Han

Förderung

  • Seoul National University

Zitieren

APA

Lee, J. H., & Han, J. P. (2024). In vivo LNP-CRISPR Approaches for the Treatment of Hemophilia. Molecular Diagnosis & Therapy. https://doi.org/10.1007/s40291-024-00705-1

Vancouver

Lee JH, Han JP. In vivo LNP-CRISPR Approaches for the Treatment of Hemophilia. Molecular Diagnosis & Therapy. 2024. doi:10.1007/s40291-024-00705-1

BibTeX
@article{Lee2024,
  author = {Lee, Jeong Hyeon and Han, Jeong Pil},
  title = {In vivo LNP-CRISPR Approaches for the Treatment of Hemophilia},
  journal = {Molecular Diagnosis & Therapy},
  year = {2024},
  doi = {10.1007/s40291-024-00705-1}
}
Kostenlos starten →